Literature DB >> 33851244

Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging.

Fabio Minutoli1,2, Riccardo Laudicella1,3, Irene A Burger3,4, Sergio Baldari5,6.   

Abstract

Entities:  

Year:  2021        PMID： 33851244     DOI： 10.1007/s00259-021-05330-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  1 in total

1.  The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.

Authors:  Sara Lundsten; Diana Spiegelberg; Bo Stenerlöw; Marika Nestor
Journal:  Int J Oncol       Date:  2019-09-30       Impact factor: 5.650
  1 in total
  1 in total

1.  [68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The "Theragnomics" Concept.

Authors:  Riccardo Laudicella; Albert Comelli; Virginia Liberini; Antonio Vento; Alessandro Stefano; Alessandro Spataro; Ludovica Crocè; Sara Baldari; Michelangelo Bambaci; Desiree Deandreis; Demetrio Arico'; Massimo Ippolito; Michele Gaeta; Pierpaolo Alongi; Fabio Minutoli; Irene A Burger; Sergio Baldari
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.